ARTICLE | Finance

Arch backs Vizgen’s RNA imaging platform with $14M series A

Arch thinks Vizgen’s technology could improve transcriptome imaging, provide more insight into disease biology

January 30, 2020 9:11 PM UTC

Arch Venture Partners is adding to its portfolio of life science tool companies by co-leading a $14 million series A for Vizgen, which is developing technology the firm thinks can overcome capacity limitations of current single-cell RNA imaging technology.

Northpond Ventures also led the untranched round; the firm’s Sharon Kedar will join the board. ...

BCIQ Company Profiles

Arch Venture Partners